FY2026 EPS Estimate for Spyglass Pharma Decreased by Analyst

Spyglass Pharma, Inc. (NASDAQ:SGP – Free Report) – HC Wainwright cut their FY2026 earnings estimates for shares of Spyglass Pharma in a research note issued on Thursday, November 12th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($2.76) per share for the year, down from their previous forecast of ($2.52). HC Wainwright currently has a “Buy” rating and a $43.00 target price on the stock. The consensus estimate for Spyglass Pharma’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for Spyglass Pharma’s Q4 2026 earnings at ($0.75) EPS, Q1 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($2.64) EPS.

A number of other equities analysts also recently commented on SGP. UBS Group reaffirmed a “buy” rating on shares of Spyglass Pharma in a research note on Monday, October 5th. Stifel Nicolaus lifted their price objective on Spyglass Pharma from $42.00 to $44.00 and gave the company a “buy” rating in a research note on Friday. Citigroup raised their price target on Spyglass Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Friday. Wall Street Zen upgraded shares of Spyglass Pharma from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Finally, Weiss Ratings upgraded shares of Spyglass Pharma from a “sell (e)” rating to a “sell (d-)” rating in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.83.

Read Our Latest Report on SGP

Spyglass Pharma Price Performance

SGP opened at $32.88 on Monday. Spyglass Pharma has a 1-year low of $17.06 and a 1-year high of $39.92. The firm has a market capitalization of $1.10 billion and a price-to-earnings ratio of -4.25. The company’s 50 day simple moving average is $28.78 and its two-hundred day simple moving average is $24.83.

Spyglass Pharma (NASDAQ:SGP – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.07).

Institutional Trading of Spyglass Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of SGP. First Light Asset Management LLC purchased a new position in shares of Spyglass Pharma during the 1st quarter worth $9,716,000. Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma during the 1st quarter worth about $6,478,000. Monashee Investment Management LLC purchased a new position in shares of Spyglass Pharma during the 1st quarter worth about $2,461,000. Bank of America Corp DE acquired a new position in Spyglass Pharma during the first quarter worth approximately $726,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Spyglass Pharma in the second quarter valued at $533,000.

Spyglass Pharma Company Profile

(Get Free Report)

SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.

Read More

Earnings History and Estimates for Spyglass Pharma (NASDAQ:SGP)

Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.